These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 39620223)
1. Case report: CD7-targeted autologous CAR-T therapy for the treatment of T-cell acute lymphoblastic leukemia undergoing allogeneic peripheral blood stem cell transplantation in the long-term follow-up. Li LL; Xia YP; Li Q; Wang P; Sun PP; Wang XG; Zhang R Front Immunol; 2024; 15():1469251. PubMed ID: 39620223 [TBL] [Abstract][Full Text] [Related]
2. Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults. Kiene S; Albrecht M; Theurich S; Scheid C; Skoetz N; Holtick U Cochrane Database Syst Rev; 2024 Nov; 11(11):CD010189. PubMed ID: 39508306 [TBL] [Abstract][Full Text] [Related]
3. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Shah BD; Ghobadi A; Oluwole OO; Logan AC; Boissel N; Cassaday RD; Leguay T; Bishop MR; Topp MS; Tzachanis D; O'Dwyer KM; Arellano ML; Lin Y; Baer MR; Schiller GJ; Park JH; Subklewe M; Abedi M; Minnema MC; Wierda WG; DeAngelo DJ; Stiff P; Jeyakumar D; Feng C; Dong J; Shen T; Milletti F; Rossi JM; Vezan R; Masouleh BK; Houot R Lancet; 2021 Aug; 398(10299):491-502. PubMed ID: 34097852 [TBL] [Abstract][Full Text] [Related]
4. [Efficacy and safety of gilteritinib-based combination therapy bridging allo-HSCT in relapsed or refractory acute myeloid leukemia patients with positive FLT3-ITD mutation]. Xu Y; Zhang J; Xue SL; Miao M; Wang Y; Chen SN; Qiu HY; Wu DP Zhonghua Xue Ye Xue Za Zhi; 2024 Apr; 45(4):357-363. PubMed ID: 38951063 [No Abstract] [Full Text] [Related]
5. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone. Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924 [TBL] [Abstract][Full Text] [Related]
7. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs. Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602 [TBL] [Abstract][Full Text] [Related]
8. Trends in Surgical and Nonsurgical Aesthetic Procedures: A 14-Year Analysis of the International Society of Aesthetic Plastic Surgery-ISAPS. Triana L; Palacios Huatuco RM; Campilgio G; Liscano E Aesthetic Plast Surg; 2024 Oct; 48(20):4217-4227. PubMed ID: 39103642 [TBL] [Abstract][Full Text] [Related]
9. [Clinical efficacy and safety of blinatumomab bridging CAR-T cell therapy in the treatment of patients with adult acute B-cell lymphoblastic leukemia]. Pu Y; Zhou XY; Liu Y; Kong X; Han JJ; Zhang J; Lin ZH; Chen J; Qiu HY; Wu DP Zhonghua Xue Ye Xue Za Zhi; 2024 Apr; 45(4):339-344. PubMed ID: 38951060 [No Abstract] [Full Text] [Related]
10. CD7 CART Therapy Bridging Allo-HSCT Remarkably Improves Long-Term DFS in Refractory/Relapsed T-ALL/LBL. Li Z; Zheng Q; Yang K; Xu T; Wang L; Wang X; Wen W; Wang J; Zhao Y; Song Y; Chen C; Zhou Q; Wu T Transplant Cell Ther; 2024 Nov; ():. PubMed ID: 39603417 [TBL] [Abstract][Full Text] [Related]
11. Comparison of cognitive behaviour therapy versus activity management, both delivered remotely, to treat paediatric chronic fatigue syndrome/myalgic encephalomyelitis: the UK FITNET-NHS RCT. Crawley E; Anderson E; Cochrane M; Shirkey BA; Parslow R; Hollingworth W; Mills N; Gaunt D; Treneman-Evans G; Rai M; Macleod J; Kessler D; Pitts K; Cooper S; Loades M; Annaw A; Stallard P; Knoop H; Van de Putte E; Nijhof S; Bleijenberg G; Metcalfe C Health Technol Assess; 2024 Oct; 28(70):1-134. PubMed ID: 39485730 [TBL] [Abstract][Full Text] [Related]
12. Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study. Iyer SP; Sica RA; Ho PJ; Prica A; Zain J; Foss FM; Hu B; Beitinjaneh A; Weng WK; Kim YH; Khodadoust MS; Huen AO; Williams LM; Ma A; Huang E; Ganpule A; Nagar SD; Sripakdeevong P; Cullingford EL; Karnik S; Dequeant ML; Patel JN; He XS; Li Z; He QA; Mendonez JH; Keegan A; Horwitz SM Lancet Oncol; 2024 Nov; ():. PubMed ID: 39617017 [TBL] [Abstract][Full Text] [Related]